5 Best Biotech Stocks Under $10

2. Roivant Sciences Ltd. (NASDAQ:ROIV)

Number of Hedge Fund Holders: 28

Total Value: $955.74 million

Share Price as of August 30: $3.50

Roivant Sciences Ltd. (NASDAQ:ROIV) is a biotech company with a pipeline for developing cancer therapeutics and immunological diseases. The company made headlines when it received FDA approval for VTAMA cream on May 24. VTMA cream is the first steroid-free treatment approved by the regulatory body for psoriasis. 

Neena Bitritto-Garg, an analyst from Citi, kept a buy rating for the company and raised the target price from $9 to $10. According to the analyst, the product pipeline if moving at the expected pace which is a positive sign for Roivant Sciences Ltd. (NASDAQ:ROIV). 

According to Insider Monkey’s Q2 data, 28 hedge funds had stakes in Roivant Sciences Ltd. (NASDAQ:ROIV). The total value of the holdings is $955.76 million.